Back to School: How biopharma can reboot drug development. Access exclusive analysis here
OxiGene (OXGN; SSE:OXGN) said that Zybrestat combretastatin A4P ( CA4P) met
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury